Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Novel tetrapeptide may provide therapeutic target for obesity and diabetes mellitus
March 6th, 2006
A novel tetrapeptide may provide a therapeutic target for obesity and type 2 diabetes mellitus. According to recent research from India, "Protein tyrosine phosphatase 1B (PTP1B) has been shown to be a negative regulator of insulin signaling by dephosphorylating key tyrosine residues within the regulatory domain of the P-subunit of the insulin receptor. Recent gene knockout studies in mice have shown the mice to have increased insulin sensitivity and improved glucose tolerance." "Furthermore," remarked G.S. Rao and colleagues, All India Institute of Medical Sciences, "these mice also exhibited a resistance to diet induced obesity. Inhibitors of PTP1B...
Source: Obesity & Diabetes Week (2006-03-06)
|
